- Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention
- Factor Xia was first noticed as a potential approach to thrombosis because people with little... read more
New Data from CytoReason published in Gut outlines the role of a new technological platform approach that has revealed a new blood-based biomarker that is 94% accurate in pretreatment... read more
Showed that treatment with esketamine resulted in a statistically significant, clinically meaningful... read more
Alkermes today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461, a novel, once-daily, oral investigational medicine... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,